Novo
Novo is a provider of investment and asset management services for the start-ups.
Business Model:
Revenue: $0
Employees: 201-500
Rankings
Industries / Tags:
Detailed Novo Information
Geographic Data
Address: Tuborg Havnevej 19
City: Hellerup
State: central jutland
Zip: 2900
Country: DK
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Metrics
2,993,709Website Global Rank
4,919Website Monthly Traffic
Twitter Followers
Description
Novo is a provider of investment and asset management services for the start-ups.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2015 | Nkarta Therapeutics | Series A | 11M |
| 5/2005 | BioMimetic Therapeutics | Series C | 11.8M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 10/2010 | ProteinSimple | Series F | 20M |
| 11/2016 | Acesion Pharma | Series C | 10.1M |
| 1/2012 | Galecto | Seed Round | - |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 3/2022 | Qure AI | Series C | 0 |
| 7/2014 | Sonion | Venture Round | - |
| 12/2012 | Rainier Therapeutics | Series A | 20M |
| 3/2023 | Clever Care Health Plan Inc. | Series C | 0 |
| 5/2013 | IVERIC bio | Private Equity Round | 125M |
| 4/2021 | Halodoc | Series C | 0 |
| 9/2019 | STipe Therapeutics | Series A | 21.8M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 2/2022 | Biomason | Series C | 0 |
| 5/2019 | Oxford BioMedica | Post-IPO Equity | - |
| 4/2023 | Alentis Therapeutics | Series C | 0 |
| 7/2021 | Aristea Therapeutics | Series B | 0 |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 1/2017 | Macrophage Pharma | Series A | 0 |
| 2/2022 | Centauri Therapeutics | Series A | 0 |
| 4/2010 | Orexo | Post-IPO Equity | - |
| 1/2011 | Adenium Biotech ApS | Seed Round | - |
| 2/2016 | Synlab | Venture Round | - |
| 5/2013 | IVERIC bio | Private Equity Round | 50M |
| 11/2022 | Breye Therapeutics | Seed Round | 0 |
| 10/2018 | Galecto | Series C | 90.2M |
| 4/2010 | Archimedes Pharma | Series C | 99M |
| 1/2007 | Lux Biosciences | Series A | 30.5M |
| 9/2014 | Pulmologix | Venture Round | 12.4M |
| 11/2018 | Precirix | Series A | 41.9M |
| 2/2013 | Avilex Pharma | Venture Round | - |
| 2/2016 | Minervax | Venture Round | 2.5M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 5/2020 | Exscientia | Series C | 60M |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 5/2014 | Tarsa Therapeutics | Series B | 0 |
| 10/2019 | Reapplix | Venture Round | 3.7M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 7/2015 | KalVista Pharmaceuticals | Series B | 33M |
| 8/2007 | IVERIC bio | Series A | 36M |
| 4/2020 | Kebotix | Series A | 0 |
| 9/2016 | Reapplix | Venture Round | 3M |
| 10/2013 | Galecto | Series B | 6.3M |
| 3/2021 | ZELP | Series A | 10M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2012 | PTC Therapeutics | Private Equity Round | 30M |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 1/2002 | Symphogen | Series B | 0 |
| 10/2019 | Disc Medicine | Series A | 50M |
| 12/2014 | Acesion Pharma | Series B | 2.5M |
| 6/2006 | Lux Biosciences | Series A | 8.4M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 6/2001 | BioMimetic Therapeutics | Venture Round | - |
| 6/2020 | Freeline | Series C | 80M |
| 4/2023 | ADCendo | Series A | 0 |
| 4/2019 | Inozyme | Series A | 67.4M |
| 5/2020 | Hyperbio Therapeutics | Venture Round | - |
| 3/2018 | NMD Pharma | Series A | 47M |
| 8/2018 | MDLIVE | Venture Round | 50M |
| 7/2008 | Cytochroma | Series C | 0 |
| 8/2011 | KalVista Pharmaceuticals | Series A | 13.2M |
| 7/2015 | PROCEPT BioRobotics | Series D | 0 |
| 12/2014 | Glionova | Series A | 5.7M |
| 3/2003 | Corus Pharma | Series B | 40M |
| 9/2004 | Arakis Limited | Series C | 51.6M |
| 8/2018 | Therachon | Series B | 60M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 6/2021 | Quanta | Series D | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 1/2004 | PTC Therapeutics | Series E | 35M |
| 11/2021 | Clever Care Health Plan | Venture Round | - |
| 12/2001 | Cytochroma | Series B | 2.2M |
| 1/2012 | Chr. Hansen | Post-IPO Secondary | 711.3M |
| 7/2020 | ISD-Immunotech | Venture Round | - |
| 11/2004 | Symphogen | Series C | 0 |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 5/2019 | Tempus | Series F | 0 |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 10/2019 | Clario | Private Equity Round | - |
| 11/2020 | Stargazer Pharmaceuticals | Series A | 0 |
| 12/2020 | Hemab | Seed Round | - |
| 1/2022 | Medical Knowledge Group | Venture Round | - |
| 7/2017 | Antag Therapeutics | Series A | 3.1M |
| 11/2003 | Protein Forest | Series A | 19M |
| 10/2019 | Allievex | Series A | - |
| 9/2013 | Acacia Pharma | Series B | 23.5M |
| 5/2015 | Biosyntia | Seed Round | 1.9M |
| 5/2014 | LYSOGENE | Series A | 22M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 3/2023 | FIRE1 | Venture Round | 0 |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 7/2007 | Reata Pharmaceuticals | Series E | 25M |
| 5/2013 | Symphogen | Private Equity Round | 0 |
| 11/2019 | WCG | Private Equity Round | - |
| 10/2012 | Affimed | Series D | 20.1M |
| 1/2016 | Tarveda Therapeutics | Series C | 38M |
| 6/2021 | BBI Group | Venture Round | - |
| 1/2020 | VectivBio | Series A | 35M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 5/2017 | AFYX Therapeutics | Series A | 17.6M |
| 4/2012 | Inogen | Venture Round | 20M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 12/2018 | Aristea Therapeutics | Series A | 15M |
| 9/2018 | BioPhero | Seed Round | 3.5M |
| 7/2010 | Reata Pharmaceuticals | Venture Round | 0 |
| 2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
| 1/2023 | Evosep | Venture Round | 0 |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 9/2001 | PTC Therapeutics | Series D | 0 |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 5/2021 | AMSilk | Series C | 0 |
| 9/2020 | Syndesi Therapeutics | Series A | 7M |
| 10/2020 | MycoWorks | Series B | 0 |
| 2/2020 | MycoWorks | Series A | 0 |
| 5/2006 | Celltrix | Venture Round | 3.9M |
| 5/2020 | IO Biotech | Debt Financing | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 12/2009 | IVERIC bio | Series B | 30M |
| 2/2012 | Altheos | Series A | 12.5M |
| 5/2004 | Panacos Pharmaceuticals | Post-IPO Equity | 0 |
| 9/2011 | Orphazyme | Series A | 0 |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 10/2005 | Salmedix | Series C | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2023 | Hemab | Series B | 0 |
| 5/2021 | Noom | Series F | 540M |
| 10/2001 | Cytochroma | Series B | 7.6M |
| 9/2012 | Karus Therapeutics | Series B | 7.6M |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 10/2019 | Arcellx | Series B | 0 |
| 6/2021 | Glycomine | Series B | 0 |
| 11/2007 | AnaptysBio | Series B | 0 |
| 11/2022 | Roslin Technologies | Series A | 12.3M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 9.1M |
| 7/2021 | Availity | Secondary Market | - |
| 8/2019 | Glycomine | Series B | 0 |
| 6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
| 3/2021 | Exscientia | Series C | 0 |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 1/2011 | Symphogen | Venture Round | 0 |
| 1/2023 | LePure Biotech | Series C | - |
| 1/2014 | Minervax | Venture Round | 4M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 11/2004 | BioMimetic Therapeutics | Series C | 25.7M |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 2/2012 | Apollo Endosurgery | Series B | 0 |
| 5/2022 | Engimmune Therapeutics | Seed Round | 15.8M |
| 6/2004 | PTC Therapeutics | Series E | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 5/2021 | Chromologics | Seed Round | 0 |
| 7/2021 | Genomatica | Series C | 0 |
| 4/2009 | ProteinSimple | Series C | 10M |
| 12/2009 | PTC Therapeutics | Venture Round | 50M |
| 1/2019 | Minervax | Grant | 5M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 8/2022 | MedGenome | Venture Round | 0 |
| 6/2007 | Logical Therapeutics | Series B | 30M |
| 4/2011 | Cianna Medical | Series B | 0 |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 6/2018 | Inthera Bioscience | Series A | 0 |
| 10/2015 | Symphogen | Debt Financing | 0 |
| 12/2020 | Tempus | Series G | 200M |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 9/2022 | Kate Farms | Series C | 75M |
| 12/2005 | CardioOptics | Series B | 20.5M |
| 7/2020 | Reapplix | Series A | 22.9M |
| 5/2022 | Nuvig Therapeutics | Series A | 47M |
| 3/2022 | Rondo Therapeutics | Series A | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 4/2010 | Altheos | Series A | 20M |
| 3/2013 | PTC Therapeutics | Private Equity Round | 60M |
| 4/2020 | Avalyn Pharma | Series B | 35.5M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 3/2023 | Chromologics | Seed Round | 0 |
| 5/2022 | Invetx | Series B | 0 |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 11/2020 | The Protein Brewery | Series A | 0 |
| 10/2021 | BIOMILQ | Series A | 0 |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 7/2021 | Hemab | Series A | 0 |
| 2/2007 | Inogen | Series D | 22M |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 9/2020 | Galecto | Series D | 0 |
| 5/2023 | Ray Therapeutics | Series A | 0 |
| 3/2020 | Tempus | Series G | 0 |
| 10/2009 | Lux Biosciences | Series B | 50M |
| 5/2014 | iRhythm Technologies | Series E | 27.3M |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 11/2022 | iECURE | Series A | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 1/2022 | Zhenge Biotech | Series C | 100M |
| 6/2018 | NBE-Therapeutics | Series B | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 12/2016 | HepaRegeniX | Series A | 9.5M |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 4/2021 | ADCendo | Series A | 61.8M |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 8/2020 | Mission Bio | Series C | 0 |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 5/2010 | Logical Therapeutics | Series C | 16.9M |
| 6/2006 | Reata Pharmaceuticals | Series D | 0 |
| 7/2008 | AlloCure | Series A | 14.5M |
| 4/2021 | Exscientia | Series D | 225M |
| 10/2003 | Nuevolution | Series B | 0 |
| 1/2017 | NeRRe Therapeutics | Series B | 28.6M |
| 5/2003 | BioMimetic Therapeutics | Series B | 5M |
| 9/2020 | Chromologics | Seed Round | 0 |
| 2/2022 | NMD Pharma | Venture Round | 0 |
| 3/2022 | Precirix | Series B | 0 |
| 1/2010 | Alios BioPharma | Venture Round | 1M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 3/2012 | Tarsa Therapeutics | Series B | 28M |
| 11/2013 | Delenex Therapeutics | Series A | 8M |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 7/2011 | Vantia | Series B | 6.5M |
| 4/2014 | Spinifex Pharmaceuticals | Series C | 45M |
| 5/2017 | Inthera Bioscience | Series A | 0 |
| 3/2021 | Deep Branch Biotechnology | Series A | 0 |
| 7/2011 | HTG Molecular Diagnostics | Series D | 0 |
| 8/2021 | Doctor Anywhere | Series C | 0 |
| 4/2004 | Corus Pharma | Series C | 0 |
| 2/2017 | Tarveda Therapeutics | Series D | 30M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 3/2014 | ZS Pharma | Series D | 0 |
| 1/2022 | Verana Health | Series E | 0 |
| 1/2017 | Avalyn Pharma | Series A | 0 |
| 5/2017 | Genoa Pharmaceuticals | Series A | 62M |
| 7/2020 | Praxis Precision Medicines | Series C | 0 |
| 6/2021 | Tribune Therapeutics | Venture Round | - |
| 8/2018 | Tel Aviv Stock Exchange | Venture Round | - |
| 6/2007 | Serentis | Series A | 20.5M |
| 9/2018 | Envirotainer | Private Equity Round | - |
| 5/2021 | Numab | Series C | 110.6M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 5/2010 | Nanoference | Venture Round | - |
| 1/2016 | NMD Pharma | Grant | 358.3k |
| 1/2021 | Corwave | Series C | 43.2M |
| 11/2007 | F-Star Therapeutics | Series A | 4.4M |
| 2/2019 | Bolt | Series B | 54M |
| 4/2012 | AlloCure | Series B | 25M |
| 7/2015 | Dades | Venture Round | - |
| 1/2016 | Acesion Pharma | Venture Round | 6M |
| 8/2019 | LanzaTech | Series E | 72M |
| 8/2020 | NREP | Venture Round | - |
| 8/2013 | ObsEva | Series A | 34.5M |
| 5/2013 | Xellia Pharmaceuticals | Venture Round | - |
| 12/2016 | Hoba Therapeutics | Seed Round | 2M |
| 2/2023 | Aquafortus | Series A | 0 |
| 6/2023 | Octave | Series C | 0 |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 8/2020 | ReViral | Series C | 0 |
| 3/2017 | ConvaTec | Post-IPO Equity | 1.3B |
| 3/2021 | BioPhero | Series A | 16.8M |
| 10/2019 | Cyteir Therapeutics | Series B | 40.2M |
| 1/2022 | Metagenomi | Series B | 0 |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 1/2017 | Amra | Venture Round | 8.9M |
| 6/2006 | MediQuest Therapeutics | Series A | 0 |
| 12/2009 | ProteinSimple | Venture Round | 4M |
| 2/2021 | Vestaron | Series B | 0 |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 8/2022 | Vestaron | Series C | 0 |
| 4/2023 | AMSilk | Series C | 0 |
| 12/2004 | Novexel | Series A | 53.6M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2019 | Vestaron | Series B | 0 |
| 2/2023 | Elo Life Systems | Series A | 0 |
| 10/2020 | VectivBio | Equity | 110M |
| 12/2017 | NorthSea Therapeutics | Series A | 29.4M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 4/2021 | The Renewable Energy Partnership | Venture Round | - |
| 12/2015 | Inthera Bioscience | Seed Round | 0 |
| 6/2016 | F2G | Series E | 60M |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 10/2019 | INBRACE | Series C | 45M |
| 12/2022 | Doctor Anywhere | Series C | 0 |
| 7/2016 | NMD Pharma | Venture Round | 3M |
| 3/2017 | Orphazyme | Venture Round | 0 |
| 10/2020 | Evotec | Post-IPO Equity | 293.6M |
| 9/2014 | Affimed | Series E | 0 |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 11/2016 | Corwave | Series B | 17.1M |
| 11/2021 | Asgard Therapeutics | Seed Round | 0 |
| 1/2007 | Cytochroma | Series C | 0 |
| 1/2014 | IVERIC bio | Post-IPO Equity | 41.7M |
| 2/2011 | Orphazyme | Seed Round | - |
| 8/2008 | Serentis | Series A | 10.1M |
| 10/2019 | Draupnir Bio | Venture Round | 33M |
| 6/2020 | Antag Therapeutics | Venture Round | 0 |
| 1/2023 | Metagenomi | Series B | 0 |
| 12/2021 | 21st.BIO | Venture Round | 97.1M |
| 5/2016 | Clario | Venture Round | - |
| 4/2014 | SI-BONE | Venture Round | 33M |
| 2/2017 | Evotec | Post-IPO Equity | 96.1M |
| 12/2012 | NeRRe Therapeutics | Series A | 18.4M |
| 9/2021 | Orbis Medicines | Venture Round | - |
| 12/2001 | Nuevolution | Series A | 0 |
| 5/2022 | Vestaron | Series C | 0 |
| 1/2006 | Symphogen | Series D | 0 |
| 12/2008 | Epitherapeutics | Funding Round | - |
| 1/2020 | HepaRegeniX | Series B | 12.2M |
| 6/2023 | Octave | Series C | 0 |
| 5/2023 | Ray Therapeutics | Series A | 0 |
| 4/2023 | Alentis Therapeutics | Series C | 0 |
| 4/2023 | ADCendo | Series A | 0 |
| 4/2023 | AMSilk | Series C | 0 |
| 3/2023 | FIRE1 | Venture Round | 0 |
| 3/2023 | Clever Care Health Plan Inc. | Series C | 0 |
| 3/2023 | Chromologics | Seed Round | 0 |
| 2/2023 | Aquafortus | Series A | 0 |
| 2/2023 | Hemab | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 11/2022 | KabaFusion | |
| 1/2022 | The Ritedose Corporation | |
| 6/2021 | BBI Group | |
| 2/2021 | Altasciences | |
| 5/2019 | Oxford BioMedica | |
| 7/2014 | Sonion A/S |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
